ウイルスベクターおよびプラスミドDNA製造市場- 世界の産業規模、シェア、動向、機会および予測、製品タイプ別、用途別、地域別、競争別、2020-2030F

ウイルスベクターおよびプラスミドDNA製造の世界市場規模は2024年に68億米ドルとなり、予測期間中は安定した成長を遂げ、2030年までの年間平均成長率（CAGR）は10.85％と予測されています。

ウイルスベクターやプラスミドDNAの生産は、バイオテクノロジーやバイオ医薬品業界において、特に遺伝子治療、ワクチン開発、遺伝子工学への応用において基盤となるプロセスです。これらのプロセスには、分子生物学や医学研究において重要なツールとなるウイルスベクターやプラスミドDNAの生産と精製が含まれます。

市場促進要因

バイオ医薬品研究開発への投資の増加

主な市場課題

コストと価格圧力

主要市場動向

細胞・遺伝子治療エコシステムの拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のウイルスベクターおよびプラスミドDNA製造市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（プラスミドDNA、ウイルスベクター、非ウイルスベクター）
  • 用途別（がん、遺伝性疾患、感染症、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域のウイルスベクターおよびプラスミドDNA製造市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のウイルスベクターおよびプラスミドDNA製造市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のウイルスベクターおよびプラスミドDNA製造市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のウイルスベクターおよびプラスミドDNA製造市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのウイルスベクターおよびプラスミドDNA製造市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のウイルスベクターおよびプラスミドDNA製造市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Oxford Biomedica PLC
• Cognate BioServices Inc.
• Cell and Gene Therapy Catapult Ltd.
• FinVector Vision Therapies
• Fujifilm Holdings Corporation（Fujifilm Diosynth Biotechnologies）
• SIRION Biotech GmbH
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Uniqure NV
• Catalent Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

The global market for viral vector and plasmid DNA manufacturing was valued at USD 6.80 billion in 2024 and is projected to experience steady growth over the forecast period, with a compound annual growth rate (CAGR) of 10.85% through 2030.

Viral vector and plasmid DNA production are foundational processes within the biotechnology and biopharmaceutical industries, especially for applications in gene therapy, vaccine development, and genetic engineering. These processes involve the production and purification of viral vectors and plasmid DNA, which serve as critical tools in molecular biology and medical research.

Key Market Drivers

Increased Investment in Biopharmaceutical R&D

The market is primarily driven by the surge in investment toward gene therapy research and development. Both viral vectors and plasmid DNA are integral to gene therapy products, which are gaining traction as promising treatments for rare and genetic diseases. These innovations have attracted significant funding from both public and private sectors.

As biopharmaceutical companies continue to expand their R&D budgets, there is a clear strategic emphasis on advanced therapies such as gene and cell therapies and DNA-based vaccines. In 2023, the top 20 global pharmaceutical firms-including Swiss leaders Novartis and Roche-collectively invested USD 145 billion in R&D, marking a 4.5% year-over-year increase. This sustained investment underscores a commitment to pipeline expansion and innovation-led growth, heavily reliant on viral vectors and plasmid DNA for therapeutic delivery.

Consequently, the rising number of research programs and preclinical studies is driving robust demand for high-quality viral vectors and plasmids. Manufacturers and suppliers are witnessing increased order volumes, more contract development opportunities, and the formation of long-term strategic partnerships.

Key Market Challenges

Cost and Pricing Pressures

The production of viral vectors and plasmid DNA is technically complex, involving multiple stages and specialized materials and equipment. As gene therapy moves from the research phase to commercial-scale manufacturing, companies face significant challenges in scaling up operations while maintaining stringent quality standards.

Achieving cost efficiencies without compromising product integrity is a persistent concern. In addition, compliance with strict regulatory frameworks necessitates investments in quality assurance, documentation, and control systems, adding to operational costs.

Establishing and maintaining GMP-compliant manufacturing facilities and cleanrooms requires substantial capital investment. Moreover, fluctuations in the prices of key raw materials-such as cell culture media, growth factors, and purification reagents-can further elevate production costs. Regulatory requirements for the safe disposal of biological and hazardous waste also contribute to financial pressure.

Key Market Trends

Expansion of the Cell and Gene Therapy Ecosystem

The development of the cell and gene therapy ecosystem is being propelled by collaborative efforts among academic institutions, research centers, and biopharmaceutical companies. These partnerships facilitate knowledge sharing, innovation, and resource pooling, accelerating the advancement of next-generation therapies.

Several countries have established dedicated research hubs and institutes focused on cell and gene therapy, providing infrastructure and a collaborative environment for scientific innovation. Notable biotech clusters-such as the Boston-Cambridge corridor in the United States and the Golden Triangle in the United Kingdom-serve as innovation centers, drawing investment and talent. Furthermore, increased funding and grant initiatives from both governmental and private sources continue to support the growth and maturation of the sector, reinforcing its long-term potential.

Key Market Players

• Oxford Biomedica PLC
• Cognate BioServices Inc.
• Cell and Gene Therapy Catapult Ltd.
• FinVector Vision Therapies
• Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
• SIRION Biotech GmbH
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Uniqure NV
• Catalent Inc.

Report Scope:

In this report, the Global Viral Vector and Plasmid DNA Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:

• Plasmid DNA
• Viral Vector
• Non-viral Vector

Viral Vector and Plasmid DNA Manufacturing Market, By Application:

• Cancer
• Genetic Disorder
• Infectious Disease
• Other

Viral Vector and Plasmid DNA Manufacturing Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector and Plasmid DNA Manufacturing Market.

Available Customizations:

Global Viral Vector and Plasmid DNA Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Plasmid DNA, Viral Vector, Non-viral Vector)
  • 5.2.2. By Application (Cancer, Genetic Disorder, Infectious Disease, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
  • 6.3.2. India Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Australia Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
  • 6.3.4. Japan Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By Application
  • 6.3.5. South Korea Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By Application

7. Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Spain Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
  • 7.3.5. United Kingdom Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application

8. North America Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Mexico Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Canada Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application

9. South America Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Viral Vector and Plasmid DNA Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Oxford Biomedica PLC
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Cognate BioServices Inc.
• 16.3. Cell and Gene Therapy Catapult Ltd.
• 16.4. FinVector Vision Therapies
• 16.5. Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
• 16.6. SIRION Biotech GmbH
• 16.7. Merck KGaA
• 16.8. Thermo Fisher Scientific Inc.
• 16.9. Uniqure NV
• 16.10. Catalent Inc.

17. Strategic Recommendations

18. About Us & Disclaimer